EDIT vs TROW · rev $32.3M vs P/E 12, rev $7.09B
Editas Medicine Inc (EDIT) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
EDIT currently screens at market cap $375.2M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the EDIT and TROW stock pages for the full models.
Not investment advice.